Vaccine children 6-11 years, Ema starts evaluation on Moderna

The European Medicines Agency is evaluating the application to extend the use of the Moderna anti-Covid vaccine, Spikevax * to children between the ages of 6 and 11. Ema herself announces it in a note. The agency’s Committee on Medicinal Products for Human Use (CHMP) will review data on the mRna vaccine, including the results of an ongoing clinical study involving children between the ages of 6 and 11, to decide whether to recommend extending the ‘use. The timing of the evaluation, in this as in the other cases – specifies the EMA – always depends on the data sent. The process takes approximately 2 months, unless additional information or analysis is required. The CHMP’s opinion will then be forwarded to the European Commission, which will issue a final decision.